<DOC>
	<DOCNO>NCT00030186</DOCNO>
	<brief_summary>The purpose study determine response rate patient refractory , relapse poor risk AML express FLT-3 activate mutation , administer CEP-701 dosage 60 mg 2 time day .</brief_summary>
	<brief_title>Open Study CEP-701 Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation</brief_title>
	<detailed_description>This open-label study CEP-701 patient refractory , relapse , poor risk AML express FLT-3 activate mutation . Patients meet eligibility criterion enrol dosage 60 mg orally 2 time day 28 day ( 1 cycle ) . Upon completion cycle 1 , dosage may increase 80mg 2 time day decrease 40 mg 2 time day , dependent upon response 60 mg dosage .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>INCLUSION CRITERIA : patient must confirm diagnosis refractory relapse AML express FLT3 mutation patient must life expectancy 2 month patient must fully recover reversible side effect previous therapy cancer EXCLUSION CRITERIA : total bilirubin , ALT AST great 2 time upper limit normal patient &lt; 65 year age estimate creatinine clearance le 60 mL/min ; patient &gt; 65 year age serum creatinine &gt; 1.5 time upper limit normal ( ULN ) receive investigational drug within past 4 week GI disturbance/malabsorption may affect absorption CEP701 HIV positive receive NSAID within prior 14 day active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>AML</keyword>
	<keyword>FLT-3 mutation</keyword>
</DOC>